Physicist Stephen Hawking lived with motor neuron disease for longer than any other person known.Credit: Santi Visalli/Getty A man with an uncommon type of motor neuron disease experienced improved symptoms and continued to work as a physician a year after becoming the first person to receive a drug designed to target the specific genetic mutation
Change can be challenging in a relationship, even when you know it’s for the best. Samsung’s new Switchers ad campaign acknowledges that challenge, particularly when it comes to switching from iPhone to Android. Playing on classic therapy talking points, Samsung recruited celebrity clinical psychologist Orna Guralnik to help couples overcome fear, discomfort and anxiety about
Credit: Keith Chambers/SPL Symptoms for 16 people with multiple sclerosis or other autoimmune conditions improved after receiving a treatment that produced disease-fighting immune cells inside their bodies, according to results1 from a small clinical trial. Researchers say the results are exciting but the treatment needs to be tested in more people. The latest trial, published
This as-told-to essay is based on a conversation with Carla Bacon, 69, who is caring for her 70-year-old husband while working a full-time job in Oklahoma. Bacon’s husband has slowly been recovering from a stroke, and they’ve had to go into medical debt to make ends meet. This interview has been edited for length and
Shinya Yamanaka in 2012, the year he won a share of a Nobel prize.Credit: Aflo/Shutterstock Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan. Many of them call out words of
Conrad, M. et al. Cell death in cancer. Cell 189, 2322–2356 (2026). Article PubMed CAS Google Scholar Mao, C., Jiang, D., Koong, A. C. & Gan, B. Exploiting metabolic cell death for cancer therapy. Nat. Rev. Cancer 26, 27–45 (2026). Article PubMed CAS Google Scholar Amaria, R. N. et al. Neoadjuvant relatlimab and nivolumab in
